News By Tag
* Morley Research Consortium
* Georgia Tech Enterprise Innovation Institute
* Clinical Trials
* Georgia Tech
* More Tags...
News By Location
Morley Research Consortium Announces Partnership With Ga Tech Enterprise Innovation Institute
MRC's partnership with the Georgia Tech Enterprise Innovation Institute aligns CRO expertise with Georgia Tech’s network of scientists and engineers leading in the development of innovative products in Nano-Technology, Bio-Tech and Medical Devices.
"Morley Research Consortium is very excited to partner with the Georgia Tech Enterprise Innovation Group ”, said Jane Green, PhD, President and CEO of Morley Research Consortium. "It will allow us to offer our medical device clients a highly qualified medium to expedite their good manufacturing procedures (GMPs). Georgia Tech is widely recognized as being an institution of excellence. Morley is honored to partner with their GMP team to build upon Morley’s existing reputation for quality clinical research while offering broader services to our existing client base with the world class university network of Georgia Tech."
“Our collaboration represents a wonderful opportunity for the Georgia Tech GMP group to work with an organization that is already doing so much to assist the medical device community and it is located right here in Georgia,” said Ade Shitta-bey, Senior Engineering Project Manager. “I am personally excited about the work Morley does because it provides synergistic offerings to our clients with a service that is complementary in bringing a more holistic approach to the process of product commercialization to our global clients right here in the local market.”
About Morley Research Consortium: Morley Research Consortium (MRC) is a full service CRO meeting the needs of the Medical Device, Pharmaceutical and BioTech research communities. In addition to comprehensive clinical trial project management services for Phase I, Phase II, Phase III and Phase IV trials encompassing the earliest stages of protocol development through clinical trials and post-approval research, MRC provides contract management services for each aspect of the clinical trial contracting and management process. Their seasoned team of professionals have successfully managed clinical trials in a wide variety of therapeutic areas both nation wide and globally. Morley’s reputation for delivering FDA guideline Clinical Trials, on time and on budget, makes them the first choice for the clinical research community.
About Georgia Tech’s Enterprise Innovation Group: The Georgia Manufacturing Extension Partnership (GaMEP) is a program of Georgia Tech’s Enterprise Innovation Institute and is a member of the National MEP network supported by the National Institute of Standards and Technology (NIST). The GaMEP, with offices in nine regions across the state, has been serving manufacturers since 1960. GaMEP offers a solutions based approach through coaching and education designed to assure regulatory compliance, increase top line growth and reduce bottom line cost. Georgia Tech’s Enterprise Innovation Institute’s provides quality standards implementation and regulatory compliance support to the medical device industry. Georgia Tech is experienced in US FDA GMP’s and ISO 13485 and has assisted manufacturers in the implementation of GMP and ISO 13485 quality systems. GaMEP also assists manufacturers in seamlessly integrating FDA compliant quality systems with the ISO 13485:2003 standard and vice versa. Our Services include: Implementation assistance with ISO 14971 for Medical Device Risk Management; ISO 14971 Training for Medical Device Manufacturers, FDA 510(k) Submissions for Obtaining FDA Approval (Clearance); Implementation assistance with 21 CFR 820 cGMP for Medical Device Manufacturers;
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.